Amy L. Price

TL;DR: Although genotype tests can determine if a patient has a specific enzyme polymorphism, it has not been determined if routine use of these tests will improve outcomes and knowledge of the most important drugs metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and inducing drugs, can help minimize the possibility of adverse drug reactions and interactions.

TL;DR: Patients and their support systems should be educated about mood relapse, suicidal ideation, and the effectiveness of early intervention to reduce complications.

TL;DR: AMI mortality risk-adjustment methods can be meaningfully improved using present-at-admission diagnoses to identify comorbid disease and conditions related closely to AMI.

TL;DR: Large improvements in statistical performance can be achieved with the use of present-at-admission diagnoses to characterize baseline mortality risk, which is important because models with better statistical performance identify different hospitals as having better or worse than expected mortality.

TL;DR: Large improvements in statistical performance can be achieved with the use of present-at-admission diagnoses to characterize baseline mortality risk, which is important because models with better statistical performance identify different hospitals as having better or worse than expected mortality.